Clinical stage biotech company developing novel RNA-modulating drug candidates to treat rare and ultra-rare diseases. | NASDAQ: ELOX
www.eloxxpharma.com
www.eloxxpharma.com
Location: United States, Massachusetts, Waltham
Employees: 11-50
Total raised: $54M
Founded date: 2013
Investors 6
| Date | Name | Website |
| - | Medison Ve... | medisonven... |
| - | Korea Inve... | partners.k... |
| - | China Ever... | everbright... |
| - | Advent Lif... | adventls.c... |
| - | Life Scien... | lspvc.com |
| - | Pontifax V... | pontifax.c... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 27.06.2017 | Series C | $30M | - |
| 08.06.2017 | Series C | $24M | - |
Persons 1
| Date | First Name | Last Name | Title | |||
| - | Daniel | Geffken | Interim Ch... | linkedin.c... | - | - |
Mentions in press and media 11
| Date | Title | Description |
| 13.03.2024 | Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases | - |
| 05.10.2021 | Eloxx Pharmaceuticals Secures Debt Facility of Up to $30 Million from Hercules Capital | Eloxx Pharmaceuticals, Inc. announced that the company has entered into a debt facility of up to $30.0 million with Hercules Capital, Inc. Eloxx has drawn the initial tranche of $12.5 million and used the proceeds to repay in full amounts o... |
| 05.10.2021 | Hercules Capital : Eloxx Pharmaceuticals Secures Debt Facility of Up to $30 Million from Hercules Capital | WATERTOWN, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced that the company has entered into a debt facility of up to $30.0 million with Hercules Capital, Inc. (NYSE: HTGC), a specialty f... |
| 05.10.2021 | Eloxx Pharmaceuticals Secures Debt Facility of Up to $30 Million from Hercules Capital | WATERTOWN, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced that the company has entered into a debt facility of up to $30.0 million with Hercules Capital, Inc. (NYSE: HTGC), a specialty f... |
| 27.06.2017 | Term Sheet — Tuesday, June 27 | CORPORATE INNOVATION TOUR The following is from the latest print edition of Fortune, where I write a regular column about technology and startups called “Boom with a View.” Paid Content Securing the enterprise without boundaries From ExtraH... |
| 27.06.2017 | Eloxx Pharmaceuticals Raises $6M | Rehovat, Israel-based Eloxx Pharmaceuticals, which is a wholly owned subsidiary of San Diego-based Sevion Therapeutics, said it ha raised $6M as part of a Series C funding round. The funding came from Korea Investment Partners (KIP) and DSC... |
| 27.06.2017 | Korea Investment Partners backs Eloxx Pharmaceuticals’ $30m Series C | Premium Eloxx Pharmaceuticals Ltd, a clinical stage company developing therapeutics for genetic diseases caused by non-sense mutations, has secured an addition $6 million to close its Series C round at $30 million. Continue reading this sto... |
| 26.06.2017 | Eloxx Pharmaceuticals Raises US$6M in Funding | Eloxx Pharmaceuticals Ltd, a clinical stage company developing therapeutics for genetic diseases caused by nonsense mutations, raised an additional US$6m in Series C funding. The investment increased the total amount raised in the round to ... |
| 26.06.2017 | Eloxx Raises $6M | SAN DIEGO & REHOVOT, Israel & SEOUL, South Korea--(BUSINESS WIRE)--Today, Korea Investment Partners (KIP), DSC Investments, Sevion Therapeutics, Inc. (OTCQB:SVON) and Eloxx Pharmaceuticals Ltd, a clinical stage company developing th... |
| 12.06.2017 | Term Sheet — Monday, June 12 | SUNNY SUNDAY Good morning! I hope you were all enjoying a lovely Sunday while Uber’s board held a seven-hour meeting to go over the results of Eric Holder’s independent investigation on Uber’s work environment, and reporters on the beat rac... |
Show more